Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial
Journal of Affective Disorders · 2023-03 · 325 · 127-134
DOI: 10.1016/j.jad.2023.01.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2023-03. Verfasst von Gellan K Ahmed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt; Department of Child & Adolescent Psychiatry, Institute…. Hauptthemen laut MEDLINE: Ketamine, Depressive Disorder, Treatment-Resistant. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
OBJECTIVE: To evaluate the effects of ketamine treatment on depression and suicidal ideation in treatment resistant depression (TRD) and to determine whether they are influenced by other psychiatric and personality comorbidities. METHODS: A randomized double-blind parallel-arm controlled study on 36 patients with TRD. Patients were divided into two treatment groups: ketamine (K group) and placebo (P group). Patients in the K and P groups received one infusion of medicine per week for two weeks. All participants were assessed using the Structured Interview for the Five-Factor Personality Model (SIFFM), Hamilton Depression Rating Scale (HDRS), Suicide Probability Scale (SPS), and Symptom Checklist 90 (SCL 90). RESULTS: After treatment, there was a significant decrease in the total HDRS and SPS scores in the K group compared to the P group, but the magnitude of response was not influenced by the presence of other psychiatric symptoms. Regression model, only receive ketamine treatment was significant factor for improve suicide and depression scores. LIMITATIONS: lack of data on other outcomes that are important to patients (e.g., quality of life, cognition) and need for a larger sample size. CONCLUSIONS: Ketamine infusions in TRD reduce suicidal ideation and depression despite the presence other psychiatric and personality disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt; Department of Child & Adolescent Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Lond…
- Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.
- Department of Anastasia, intensive care and pain management, Faculty of Medicine, Assiut University, Assiut, Egypt.
Zitieren
APA
Ahmed, G. K., Elserogy, Y. M., Elfadl, G. M. A., Ghada Abdelsalam, K., & Ali, M. A. (2023). Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. Journal of Affective Disorders, 325, 127-134. https://doi.org/10.1016/j.jad.2023.01.005
Vancouver
Ahmed GK, Elserogy YM, Elfadl GMA, Ghada Abdelsalam K, Ali MA. Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial. Journal of Affective Disorders. 2023;325:127-134. doi:10.1016/j.jad.2023.01.005
BibTeX
@article{Ahmed2023,
author = {Ahmed, Gellan K and Elserogy, Yasser M and Elfadl, Ghada Mohammad Abo and Ghada Abdelsalam, K and Ali, Mostafa A},
title = {Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial},
journal = {Journal of Affective Disorders},
year = {2023},
volume = {325},
pages = {127--134},
doi = {10.1016/j.jad.2023.01.005}
}
EUVIMED